Diabetes Research and Clinical Practice · Nov 17, 2026
Tirzepatide and risk of nutritional deficiency anemia compared with GLP-1 receptor agonists in adults with type 2 diabetes and overweight or obesity
By Tu KC, Huang KH, Liu MY et al.
BACKGROUND: Nutritional deficiency anemia (NDA) is a potential concern during incretin-based treatment, but its comparative occurrence with tirzepatide and glucagon-like peptide-1 receptor agonists (GLP-1RAs) remains uncertain. METHODS: We conducted a retrospective cohort study using the TriNetX database. Adults with type 2 diabetes and overweight or obesity who initiated tirzepatide or a GLP-1RA between January 1, 2022, and August 31, 2026, were identified. Patients with prior use of either treatment, NDA, type 1 diabetes, or bariatric surgery were excluded. After 1:1 propensity score matching, outcomes were assessed from day 1 through day 365. The primary outcome was a composite of iron, vitamin B12, or folate deficiency anemia. RESULTS: The matched cohorts included 67,608 patients each. NDA occurred in 1,440 tirzepatide users (2.13%) and 1,917 GLP-1RA users (2.84%; hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.83-0.95). Tirzepatide was associated with less iron deficiency anemia (HR, 0.87; 95% CI, 0.81-0.93), whereas estimates for vitamin B12 deficiency anemia (1.07; 0.83-1.38) and folate deficiency anemia (0.98; 0.56-1.71) were inconclusive. CONCLUSION: Tirzepatide initiation was associated with a modestly lower hazard of diagnosed NDA, predominantly iron deficiency anemia, than GLP-1RA initiation. Residual confounding and differences in follow-up and ascertainment limit causal interpretation.
doi.org/10.1016/j.diabres.2026.113675PubMed 43044770Interventions